Boston Scientific Corporation (BSX) — ESG & Values Scores

Environment story

Boston Scientific reports ISO 14001 and ISO 50001 certifications at 18 and 14 key locations respectively, demonstrating formal environmental management infrastructure. The company discloses a commitment to renewable energy conversion and carbon offset compensation, but lacks transparent Scope 1, 2, and 3 emissions data in provided filings. Net-zero target year is not explicitly stated in accessible documents. The company acknowledges climate change risks to supply chain and operations and has undertaken EU MDR compliance costing $464M cumulatively, with estimated total of $475–525M. However, absence of quantified emission reductions, rising Scope 3 disclosure gaps (particularly related to product usage in expanding AI/computing segments), and reliance on offset language rather than operational decarbonization trigger deductions. No significant resource controversies (toxic waste, water, habitat) are documented in provided materials.

Criticisms on file

Undisclosed Scope 1, 2, and 3 emissions; no quantified net-zero target year disclosed in 10-K or proxy materials.
Source: BSX 10-K 2025, Item 1. Business - Environmental Regulation and Management; Item 1A. Risk Factors
Risk disclosure identifies climate change and extreme weather as potential threats to supply chain, manufacturing, and distribution; no formal climate scenario analysis or resilience targets disclosed.
Source: BSX 10-K 2025, Item 1A. Risk Factors - 'Natural disasters, climate change and other extreme weather'
Potential PFAS and ethylene oxide regulation compliance burden acknowledged; ongoing sterilization process challenges that could limit product manufacturing timelines.
Source: BSX 10-K 2025, Item 1A. Risk Factors - 'Disruptions in the supply of materials and components' and environmental regulation discussion

Disclosed initiatives

ISO 14001:2015 Environmental Management System Certification

18 key manufacturing and distribution locations certified for environmental management standard.

Formal framework for emissions, waste, and resource management across major facilities.
ISO 50001:2018 Energy Management System Certification

14 key locations certified for energy management standard.

Systematic approach to energy optimization and GHG reduction.
Renewable Energy and Carbon Offset Strategy

Company states commitment to 'cutting energy use, converting to renewable energy where feasible, and compensating through carbon offsets where appropriate.'

Mixed reliance on renewable transition and offsetting; operational decarbonization targets not quantified.
Supply Chain Resilience Program

Ongoing supplier resiliency program to identify and mitigate supply chain disruption risk.

Aims to reduce climate-related supply chain vulnerability.

Social story

Boston Scientific employs approximately 59,000 employees as of December 31, 2025, with 60% outside the U.S. The company demonstrates a formal commitment to diversity, equity, and inclusion through ten Employee Resource Groups (ERGs), regular pay equity audits, and executive-level oversight via the Executive Committee and Board. CEO-to-worker pay ratio is not disclosed in provided documents. Turnover rate is not quantified. The company reports sustained focus on workforce development, competitive compensation, health and safety protocols, and employee engagement surveys. Union standing is not explicitly documented; no NLRB complaints, strikes, or labor disputes within the last 24 months are reported. Supply-chain labor ethics (e.g., conflict minerals, cobalt sourcing) are not detailed in the filings reviewed. The company acknowledges responsibility for responsible sourcing and has established a supplier diversity program, but specific audit results or third-party verification of labor practices are not disclosed.

Criticisms on file

CEO-to-worker pay ratio not disclosed; no quantified executive compensation equity metrics publicly available.
Source: BSX 10-K 2025, Compensation Discussion & Analysis; BSX Proxy 2026
Workforce turnover rate not disclosed; no data on retention or employee attrition trends provided.
Source: BSX 10-K 2025, Item 1. Business - Human Capital
Supply-chain labor ethics and human-rights due diligence not detailed; no third-party audits or conflict-minerals policy disclosed in provided filings.
Source: BSX 10-K 2025, Risk Factors and Business sections

Disclosed initiatives

Ten Employee Resource Groups (ERGs)

Voluntary, company-sponsored employee groups open to all employees. Each ERG receives global and local executive sponsors and financial resources.

Fosters inclusive workplace culture and celebrates diversity; provides forums for peer learning and inclusive leadership development.
Pay Equity Audits and Benchmarking

Regular comprehensive audits, internal and external analyses, and company-wide salary benchmarking to identify and mitigate disparities.

Commitment to equal pay for equal work rooted in company values.
Competitive Compensation and Benefits

Cash-based salaries, bonus programs, stock awards, health insurance, paid time off, family leave, retirement savings, childcare, EAP, mental health resources.

Supports overall employee well-being and retention.
Health, Safety, and Well-Being Programs

Global health and safety standard protocols; Employee Health & Safety Global and Regional Councils; holistic programs addressing physical, financial, and emotional well-being.

Aims to create a safe, supportive work environment and productive workforce.
Workforce Development and Succession Planning

Robust succession planning; professional and technical training; mentoring and leadership development programs at all levels.

Prepares future leadership pipeline and supports career advancement.
Employee Engagement Surveys

Periodic surveys to solicit employee feedback on workplace experience and improve organizational responsiveness.

Supports culture of continuous listening and improvement.
Supplier Diversity Program

Inclusive supplier selection practices and support for diverse businesses in supplier network.

Extends DEI commitment to supply-chain partners.
Close the Gap Initiative

Program focused on raising healthcare provider awareness about health disparities and addressing barriers to care for underserved communities.

Contributes to social equity in healthcare access.

Governance story

Boston Scientific maintains a single-class share structure with no dual-class voting provisions, as evidenced by the Board's recommendation to approve removal of supermajority voting provisions in Proposal 5 and allowance for 25% of shareholders to call special meetings (Proposal 7). The Board comprises ten director nominees with a strong emphasis on independence and diverse expertise in healthcare, technology, finance, and governance. The Board annually elects all directors by majority vote and conducts regular performance evaluations. Board independence percentage is not quantified in provided documents but described as "strong" with 80% threshold referenced. The company maintains a Global Government Affairs presence headquartered in Washington, D.C., but specific annual lobbying expenditure is not disclosed. No active litigation related to antitrust, consumer-safety fraud, or financial misconduct is documented in the 10-K. The company has recorded a $194 million litigation charge for a legacy IP-related matter in 2025, and has previously paid intangible asset impairment charges related to acquired technology. The Board proactively removed supermajority voting provisions and established majority-vote director election standards, indicating responsive governance.

Criticisms on file

Annual lobbying expenditure not disclosed; scope and targets of government affairs activities not transparently quantified in provided filings.
Source: BSX 10-K 2025, Item 1. Business - Health Care Policies and Reimbursement; BSX Proxy 2026
$194 million litigation charge recorded in 2025 for resolution of legacy IP-related matter from acquired company; indicates post-acquisition integration risk.
Source: BSX 10-K 2025, MD&A - Litigation-related Net Charges (Credits)
$386 million intangible asset impairment charge in 2024 related to acquisitions of Cryterion and Devoro; attributed to Farapulse PFA System cannibalization of cryoablation business and program cancellation.
Source: BSX 10-K 2025, MD&A - Intangible Asset Impairment Charges
EU MDR compliance costs of $464 million incurred cumulatively through 2025; expected total $475–525 million; ongoing regulatory complexity and expense burden.
Source: BSX 10-K 2025, MD&A - EU MDR Implementation Costs

Disclosed initiatives

Annual Director Election and Performance Evaluation

All directors elected annually by majority vote; Board conducts regular self-assessments and evaluation of director performance.

Ensures accountability and regular refreshment of leadership; supports responsive governance.
Board Independence and Diversity

90% of 2026 nominees are independent; board representation includes expertise in healthcare, technology, finance, governance, and public policy; average independent director age 63.6 years; average tenure 7.8 years.

Diverse skill sets and independent oversight support effective Board function and risk oversight.
Executive Committee and Board Oversight of DEI, Compensation, and Risk

Executive Committee and Board of Directors oversee policies and strategies related to diversity and inclusion, employee engagement, talent recruitment, pay equity, and company culture.

Ensures alignment of executive and Board priorities on governance and social responsibility.
Removal of Supermajority Voting Provisions (Proposal 5)

Board recommending amendment to Certificate of Incorporation to remove supermajority voting requirements, enhancing shareholder voting power.

Increases democratization of shareholder voting and reduces barriers to shareholder action.
Special Meeting Rights (Proposal 7)

Board recommending amendment to allow shareholders holding 25% of common stock to call special meetings of stockholders.

Expands shareholder rights and governance participation.
Board Refreshment and Succession Planning

Nominating and Governance Committee reviews director tenure and continued service annually; Board not imposing term limits or mandatory retirement ages but balancing experience with fresh perspectives.

Supports effective Board evolution and knowledge continuity.
Global Government Affairs Function

Maintains Government Affairs presence headquartered in Washington, D.C. to monitor and advocate on legislative and regulatory matters affecting company and patients.

Ensures active engagement with policy stakeholders; specific advocacy positions not detailed.
Audit Committee Financial Expert Designation

Multiple Audit Committee members designated as financial experts; robust audit oversight structure.

Strengthens financial reporting integrity and risk oversight.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Boston Scientific Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Boston Scientific Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)